ParcelBio
New accelerator entry · 2024-02-07 · the record
In their words
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
What the record says
The full profile
Source Check, INVEST, RECRUIT and Press Requests on ParcelBio
- Source Check — verify what ParcelBio states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with ParcelBio for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ParcelBioYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind ParcelBio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.